Literature DB >> 6637352

The epileptogenicity of neurolept anaesthesia in patients during and after neuroradiological examinations with metrizamide.

A Rudehill, E Gordon, A Grepe, L Widén.   

Abstract

Previous experimental studies caution against the use of neurolept anaesthesia during subarachnoid injection of metrizamide for neuroradiodiagnostic procedures because of severe epileptogenic complications. To examine whether these recommendations are relevant in the clinical situation or not, 104 patients were studied. They underwent neuroradiological investigations with metrizamide subarachnoidally and were anaesthetized with neurolept anaesthesia either during the investigation (59 patients, Group I) or within 48 h afterwards (45 patients, Group II) when a neurosurgical operation was performed. In 10 patients of Group I, EEG was recorded during the investigation. All patients were observed for occurrence of clinical epileptic manifestations during and after the anaesthesia. Apart from one patient who had a short episode of suspected epileptogenic EEG-activity shortly after the injection of metrizamide, none of the other patients showed EEG-abnormalities of epileptogenic type and none of them had any clinical signs of epileptic manifestations. On the basis of the results of this clinical study it is concluded that neurolept anaesthesia does not increase the risk of epileptic complications during neuroradiological investigations with metrizamide.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6637352     DOI: 10.1111/j.1399-6576.1983.tb01952.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  Focal epileptic activity following intravenous contrast material injection in patients with metastatic brain disease.

Authors:  E Avrahami; J Weiss-Peretz; D F Cohn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-02       Impact factor: 10.154

2.  High-dose contrast-enhanced computed tomography (CECT) with iopamidol in the detection of cerebral metastases. Tolerance of the contrast agent.

Authors:  M Leonardi; A Lavaroni; E Biasizzo; G Fabris; T Penco; F Zappoli
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.